Renal Cell Carcinoma

During a Targeted Oncology™ Case-Based Roundtable™ event, Rana McKay, MD, moderated a discussion on what role risk stratification plays in selecting frontline therapy for a patient with metastatic renal cell carcinoma. This is the first of 2 articles based on this event.

Regina Barragan-Carrillo, MD, discusses findings from a large population-based study which found there to be significantly higher rates of nephrectomy among patients with renal cell carcinoma who had received prior thymectomy vs the incidence of nephrectomy overall.

During a Targeted Oncology™ Case-Based Roundtable™ event, Sumanta K. Pal, MD, and participants explored the third-line treatment options for a patient with advanced renal cell carcinoma. This is the second of 2 articles based on this event.

In an interview with Targeted Oncology, Bruno Bastos, MD, discussed how TPST-1120 can help address limited treatment options for patients with advanced renal cell carcinoma beyond immunotherapy and anti-VEGF tyrosine kinase inhibitors.

Bruno R. Bastos, MD, discusses findings from a study which assessed the pharmacodynamic and radiographic changes among patients with renal cell carcinoma who were treated with the combination of nivolumab and TPST-1120.

Subcutaneous nivolumab coformulated with rHuPH20 showed noninferiority of PK exposures compared with intravenous nivolumab in metastatic ccRCC.

Adjuvant pembrolizumab treatment significantly improved overall survival vs placebo in patients with clear cell renal cell carcinoma.

In the phase 3 CheckMate 914 trial, the use of nivolumab did not meet the primary endpoint of disease-free survival when compared to a placebo in patients with localized renal cell carcinoma at a heightened risk of relapse following nephrectomy.

Real-world, retrospective data showed that morphologic renal cell carcinoma types and tumor-stages helps to inform recurrence and prognosis.

Pembrolizumab with lenvatinib continued to demonstrate antitumor activity and led to longer survival rates vs historical controls in patients with advanced non–clear cell renal cell carcinoma.

First-line lenvatinib and pembrolizumab showed similar overall survival rates and improved progression-free survival and response rates vs global standard-of-care immunotherapies among patients with advanced renal cell carcinoma.

Martin H. Voss, MD, discusses what community oncologists should takeaway from the the extended follow-up data of the phase 2 KEYNOTE-B61 study which assessed first-line pembrolizumab plus lenvatinib for patients with non-clear cell renal carcinomas.

Patients with advanced/metastatic clear cell renal cell carcinoma who received belzutifan took longer to experience worsening symptoms and reported higher quality-of-life scores on questionnaires.

During a Targeted Oncology™ Case-Based Roundtable™ event, Sumanta K. Pal, MD, discussed the case of an older patient with metastatic renal cell carcinoma who had recurrent disease after receiving axitinib and pembrolizumb, then single-agent cabozantinib. This is the first of 2 articles based on this event.

In this Q&A discussion, Hans Hammers, MD, PhD, explains the rationale for continued use of tyrosine kinase inhibitor and PD-L1 therapy combinations, like lenvatinib and pembrolizumab, for patients with advanced renal cell carcinoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Neeraj Agarwal, MD, discussed his approach to recognizing and managing adverse events related to treatment with cabozantinib and nivolumab in patients with advanced renal cell carcinoma. This is the second article based on this event.

Pembrolizumab plus cabozantinib showed promising activity with an objective response rate of 65.8%, median progression-free survival of 10.45 months, and median overall survival of 30.81 months in metastatic renal cell carcinoma.

The landmark study, KEYNOTE-564, compared pembrolizumab vs placebo in patients with clear cell renal cell carcinoma who were at high risk for recurrence after nephrectomy.

During a Targeted Oncology™ Case-Based Roundtable™ event, Neeraj Agarwal, MD, examined the significance of the 44-month follow-up of the CheckMate 9ER trial of patients with metastatic renal cell carcinoma.

Though the combination of talazoparib and avelumab was safe as a treatment for patients with specific types of kidney cancer, the combination was not effective, according to findings from a phase 2 trial.

Belzutifan is now an FDA-approved treatment for adult patients with advanced renal cell carcinoma.

In separate live events, Yasser Mohamed Ali Ged, MBBS, and Deepak Kilari, MD, discussed the best treatment options for patients with advanced renal cell carcinoma and what role tyrosine kinase inhibitors play for these patients.

Clinical trials are shedding light into best treatment approaches for non–clear cell renal cell carcinoma, including immunotherapy plus tyrosine kinase inhibitor combinations, as discussed in Case-Based Roundtable events.

Benjamin Garmezy, MD, discusses some of the ongoing challenges or disparities seen in the community oncologist setting related to clinical trials.

During a Targeted Oncology™ Case-Based Roundtable™ event, Pedro C. Barata, MD, MSc, and participants discussed dosing and toxicity issues related to tivozanib and lenvatinib/everolimus in a patient who has received 2 prior lines of therapy for metastatic clear cell renal cell carcinoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Chandler Park, MD, reviewed the latest updates of the pivotal trials of frontline combination therapies for advanced clear cell renal cell carcinoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Arnab Basu, MD, MPH, and participants discussed issues related to the use of tivozanib and lenvatinib/everolimus as third-line therapies for patients with advanced renal cell carcinoma.

Viktor Grünwald, MD, PhD, discusses what findings from the post hoc analysis of the CLEAR trial of lenvatinib plus pembrolizumab vs sunitinib for patients with renal cell carcinoma mean for community oncologists.

Arnab Basu, MD, MPH, FACP, discusses molecular residual disease-guided adjuvant therapy in patients with renal cell carcinoma, highlighting the rationale and goals of the MRD gate RCC clinical trial.

Early trials are exploring the benefit of chimeric antigen receptor T-cell therapy in advanced renal cell carcinoma.